CHRISTOPHER MILSTEAD: Open Payments
NPI 1932216090 · FORT SMITH, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,509 in 60 payments from 15 companies in 2025. Trend: 2023 $1,709 · 2024 $1,900 · 2025 $1,509
Food & beverage: $1,502Education: $8
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 7 | $261 |
| Otsuka America Pharmaceutical, Inc. | 10 | $226 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $185 |
| ABBVIE INC. | 7 | $157 |
| Supernus Pharmaceuticals, Inc. | 5 | $155 |
| Neurocrine BioSciences, Inc. | 5 | $139 |
| Teva Pharmaceuticals USA, Inc. | 3 | $74 |
| Alkermes, Inc. | 4 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| Janssen Pharmaceuticals, Inc | 2 | $54 |
Products named: Auvelity, CAPLYTA, REXULTI, VRAYLAR, Qelbree, INGREZZA, AUSTEDO XR, ARISTADA.
Industry payments across AR — which companies pay providers there.
